Nutex Health director granted 603 RSUs

Nutex Health, Inc. director Cheryl Yvonne Grenas reported an equity award in the form of 603 restricted stock units (RSUs) on July 14, 2025.

Rhea-AI Filing Summary

Nutex Health, Inc. director Cheryl Yvonne Grenas reported an equity award in the form of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on July 14, 2026, with a provision that if she leaves the company without cause during the vesting period, the award will vest on a pro-rata basis based on her actual time in service.

Insider Trade Summary

Grant/Award: 603 shares

Grant/Award 1 txn

Insider Grenas Cheryl Yvonne

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSUs)	603	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSUs) — 603 contracts (Direct)

Footnotes (2)

1. F1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
2. F2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nutex Health (NUTX) disclose for Cheryl Grenas?

Nutex Health disclosed that director Cheryl Yvonne Grenas received an award of 603 restricted stock units on July 14, 2025. These RSUs represent future rights to Nutex common shares, subject to vesting conditions tied to her continued service with the company.

How many RSUs did Nutex Health director Cheryl Grenas receive and at what price?

Director Cheryl Yvonne Grenas received 603 restricted stock units at a price of $0 per unit. Each RSU represents the right to receive one Nutex common share with $0.001 par value when the units vest under the award’s stated conditions.

When do Cheryl Grenas’s 603 Nutex Health RSUs vest?

Cheryl Grenas’s 603 restricted stock units are scheduled to vest 100% on July 14, 2026. Vesting is contingent on continued service, though a pro-rata portion can vest earlier if she leaves the company without cause during the vesting period.

What happens to the Nutex Health RSUs if Cheryl Grenas leaves before vesting?

If Cheryl Grenas leaves Nutex Health without cause during the vesting period, her RSUs vest on a pro-rata basis. The pro-rata calculation is based on her actual time in service with the company between the grant date and her departure date.

What does each Nutex Health RSU granted to Cheryl Grenas represent?

Each RSU granted to Cheryl Grenas represents a contingent right to receive one share of Nutex Health common stock. The shares have a par value of $0.001 and are delivered only if and when the RSUs vest under the award’s terms.

Is Cheryl Grenas’s Nutex Health RSU award held directly or indirectly?

The Form 4 indicates that Cheryl Grenas’s 603 restricted stock units are held with direct ownership. The filing lists the ownership form for the derivative securities as “D,” meaning she directly holds the reported RSU award position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 12:56 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grenas Cheryl Yvonne

(Last) (First) (Middle)

6030 S. RICE AVE., SUITE C

(Street)

HOUSTON TX 77081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health, Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSUs)	$0(1)	07/14/2025		A		603(1)		07/14/2026(2)	07/14/2026(2)	Common Stock	603	$0	603	D

Explanation of Responses:

1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.

2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

	/s/ Cheryl Grenas	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.